The expression of MT1 melatonin receptor and Ki-67 antigen in melanoma malignum

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 3887-3895

  Danielczyk, Karolina ^a   Dziegiel, Piotr ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Ki 67 antigen; Malignant melanoma; Melatonin; Melatonin receptors; MT1; MT2

Indexed keywords

KI 67 ANTIGEN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; PARAFFIN;

ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MELANOMA; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECEPTOR AFFINITY; TUMOR LOCALIZATION; TUMOR VOLUME;

HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MELANOMA; NEOPLASM INVASIVENESS; RECEPTOR, MELATONIN, MT1; SKIN NEOPLASMS;

EID: 71949131087     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Pandi-Perumal SR, Srinivasan V, Maestroni GJM, Cardinali DP, Poeggeler B and Hardeland R: Melatonin: Nature's most versatile biological signal? FEBS J 273: 2813-2838, 2006.
2. Melatonin. Monograph. Alter Med Rev 10: 326-336, 2005.
3. Jung B and Ahmad N: Melatonin in cancer management: Progress and promise. Cancer Res 66: 9789-9793, 2006. (Pubitemid 44672026)
4. Paakonen T, Makinen TM, Leppaluoto J, Rintamäki H, Palinkas LA and Hassi J: Urinary melatonin: a noninvasive method to follow human pineal function as studied in three experimental conditions J Pineal Res 40: 110-115, 2006.
5. Blask DE, Sauver LA and Dauchy RT: Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanism of action and their implications for circardian-based cancer therapy. Curr Top Med Chem 2: 113-132, 78, 2002.
6. Dziegiel P, Murawska-Cialowicz E, Jethon Z, Januszewska L, Podhorska-Okolow M, Surowiak P, Zawadzki M, Rabczynski J and Zabel M: Melatonin stimulates the activity of protective antioxidative enzymes in myocardial cells of rats in the course of doxorubicin intoxication. J Pineal Res 35: 183-187, 2003. (Pubitemid 37100396)
7. Dziegiel P, Podhorska-Okolow M and Zabel M: Melatonin: Adjuvant therapy of malignant tumors. Med Sci Monit 14: RA64-70, 2008.
8. Izykowska I, Piotrowska A, Podhorska-Okołow M, Cegielski M, Zabel M and Dziegiel P: Protective role of melatonin during exposure to UV light. Postȩpy Hig Med Dosw 62: 23-27, 2008. (in Polish).
9. Reiter RJ, Tan DX, Gitto E, Sainz RM, Mayo JC, Leon J, Manchester LC, Vijayalaxmi E and Kilic U: Pharmacological utility of melatonin in reducing oxidative cellular and molecular level. Pol J Pharmacol 56: 159-170, 2004. (Pubitemid 38931382)
10. Smirnov AN: Nuclear melatonin receptors. Biochemistry 66: 19-26, 2001.
11. Barret P, Conwey S and Morgan PJ: Digging deep - structure - function relationships in the melatonin receptor family. J Pineal Res 35: 221-230, 2003.
12. Macchi MM and Bruce JN: Human pineal physiology and functional significance of melatonin. Front Neuroendocrinol 25: 177-195, 2004. (Pubitemid 39642189)
13. Sallinen P, Saarela S, Ilves M, Vakkuri O and Leppaluoto J: The expression of MT1 and MT2 melatonin receptor mRNA in several rat tissues. Life Sciences 76: 1123-1134, 2005.
14. Nosjean O, Ferro M, Coge F, Beauverger P, Henlin JM, Lefoulon F, Fauchere JZ, Delagrange P, Canet E and Boutin JA: Identification of the melatonin- binding site MT3 as quinine reductase 2. J Biol Chem 275: 31311-31317, 2000. (Pubitemid 30757798)
15. Reppert SM, Weaver DR and Ebisawa T: Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circardian responses. Neuron 13: 1177-1185, 1994.
16. Slominski A, Wortsman Derma and Tobin DJ: The cutaneous serotoninergic/melatoninergic system securing a place under the sun. FASEB J 19: 174-194, 2005. (Pubitemid 40189259)
17. Ekmekcioglu C: Melatonin receptors in humans: biological role and clinic relevance. Biomed Pharmacother 60: 97-108, 2006.
18. Gall Ch, Stehle JH and Weaver DR: Mammalian melatonin receptors: molecular biology and signal transduction. Cell Tissue Res 309: 151-162, 2002. (Pubitemid 34744037)
19. Morgan PJ, Barrett P, Hazlerigg D, Milligan G, Lawson W, MacLean A and Davidson G: Melatonin receptors couple through a cholera toxin-sensitive mechanism to inhibit cyclic AMP in the ovine pituitary. J Neuroendocrinol 7: 361-369, 1995.
20. Masana MI and Dubocovich ML: Melatonin receptor signaling: finding the path through the dark. Sci STKE.107:PE39, 2001.
21. Witt-Enderby PA, Bennett J, Jarzynka MJ, Firestine S and Melan MA: Melatonin receptors and their regulation: biochemical and structural mechanism. Life Sciences 72: 2183-2198, 2003. (Pubitemid 36292142)
22. Gollob JA, Scott W, Carter C and Kelley SL: Role of Raf kinase in cancer: Therapeutic potential of targeting the Raf/Mek/Eerk signal transduction pathway. Sem Oncol 33: 392-406, 2006. (Pubitemid 44142735)
23. Cos S, Garcia-Bolado A and Sanchez-Barcelo EJ: Direct antiproliferative effects of melatonin on two metastatic cell sublines of mause melanoma (B16, PG19). Melanoma Res 11: 197-201, 2001. (Pubitemid 32385825)
24. Kadekaro AL, Andrade LS, Floeter-Winter LM, Rollag MD, Virador V, Veira W and Castrucci AM: MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 36: 204-211, 2004. (Pubitemid 38429287)
25. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L and Hill SM: Involvement of the MT1 melatonin receptor in human breast cancer. Cancer Letters 179: 141-150, 2002. (Pubitemid 34215105)
26. Dziegiel P and Zabel M: Role of immunohistochemical expression of Ki-67 in adenocarcinoma of large intestine. In: Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Hayat MA (ed.). London, Elsevier Academic Press, pp. 127-134, 2006.
27. Gerdes J, Schwab U, Lemke H and Stein H: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983. (Pubitemid 13179545)
28. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
29. Szczuraszek K, Mazur G, Jelen M, Dziegiel P, Surowiak P and Zabel M: Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. Anticancer Res 28: 1113-1118, 2008. (Pubitemid 351578962)
30. Brown DC and Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503, 1990.
31. Ruka Haski and Nowecki Z: Dermal melanoma. Recommendations for diagnostic-therapeutic procedures. Polska Unia Onkologii, Warszawa, pp. 321-333, 2003 (in Polish).
32. Rigell DS and Carucci JA: Malignant melanoma: prevention, early detection and treatment in the 21 - st century. CA Cancer J Clin 50: 215-236, 2000.
33. Carlson JA, Ross JS, Slominski A, Linette G, Mysliborski J, Hill J and Mihm M Jr: Molecular diagnostics in melanoma. J Am Acad Dermat 52: 743-775, 2005.
34. Breslow A: Thicness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 172: 902-908, 1970.
35. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987
36. Fisher TW, Zmijewski MA, Zbytek B, Sweatman TW, Slominski RM, Wortsman J and Slominski A: Oncostatic effects of the indole melatonin and expression of its cytosolic and nuclear receptors in cultured human melanoma cell lines. Inter J Oncol 29: 665-672, 2006.
37. Tam CW, Chan KW, Liu VWS, Pang B, Yao KM and Shiu SY: Melatonin as a negative mitogenic hormonal regulator of human prostatpithelial cell growth: potential mechanisms and clinical significance. J Pineal Res 45: 403-412, 2008.
38. Fic M, Podhorska - Okołow M, Dziegiel P, Gebarowska E, Wysocka T and Zabel M: Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell-line A-549, laryngeal cancer line HEp-2) In Vivo 21: 513-518, 2007.
39. García-Navarro A, González-Puga C, Escames G, López LC, López A, López- Cantarero M, Camacho E, Espinosa A, Gallo MA and Acuña-Castroviejo D: Cellular mechanisms involved in the melatonin inhibition of HT-29 human colon cancer cell proliferation in culture. J Pineal Res 43: 195-205, 2007.
40. García-Santos G, Antolín I, Herrera F, Martín V, Rodriguez-Bianco J, del Pilar Carrera M and Rodriguez C: Melatonin induces apoptosis in human neuroblastoma cancer cells. J Pineal Res 41: 130-135, 2006. (Pubitemid 44141747)
41. Pandey S, Lopez C and Jammu A: Oxidative stress and activation of proteasome protease during serum deprivation-induced apoptosis in rat hepatoma cells; inhibition of cell death by melatonin. Apoptosis 8: 497-508, 2003. (Pubitemid 37247992)
42. Roth JA, Rosenbatt T, Lis A and Bucelli R: Melatonin-induced suppression of PC12 cell growth is mediated by its Gi-coupled transmembrane receptors. Brain Res 919: 139-146, 2001. (Pubitemid 33016597)
43. Wed S, Kim B, Ottenhof T, Brown GM, Werstiuk ES and Niles LP: Human melatonin MT1 receptor induction by valproic acid and its effects in combination with melatonin on MCF-7 breast cancer cell proliferation. Eur J Pharmacol 560: 17-22, 2007. (Pubitemid 46320399)
44. Xi SC, Tam PC, Brown GM, Pang SF and Shiu SY: Potential involvement of MT1 receptor and attenuated sex steroid-induced calcium influx in the direct antiproliferative action of melatonin on androgen-responsive LNCaP human prostate cancer cells. J Pineal Res 29: 172-183, 2000.
45. Lenoir V, de Jonage-Canonico MB, Perrin MH, Martin A, Scholler R and Kerdelhué B: Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a]anthracene in the female Sprague-Dawley rat. Breast Cancer Res 7: 470-476, 2005.
46. Ying SW, Niles LP and Crocker C: Human malignant melanoma cells express high affinity receptors for melatonin: antiproliferative effects of melatonin and 6- chloromelatonin. Eur J Pharmacol 246: 89-96, 1993.
47. Gitto E, Tan DX, Reiter RJ, Karbownik M, Manchester LC, Cuzzocrea S, Fulia F and Barberi I: Individual and synergistic antioxidative actions of melatonin: studies with vitamin E, vitamin C, glutathione and desferrioxamine (desferoxamine) in rat liver homogenates. J Pharm Pharmacol 53: 1393-1401, 2001. (Pubitemid 32982257)
48. Montilla P, Tunez I, Munoz MC, Soria JV and López A: Antioxidative effect of melatonin in rat brain oxidative stress induced by adriamycin. Rev Esp Fisiol 53: 301-305, 1997. (Pubitemid 28013162)
49. Dillon DC, Easley SE, Asch BB, Cheney RT, Brydon L, Jockers R, Winston JS, Brooks JS, Hurd T and Asch HL: Differential expression of high-affinity melatonin receptors (MT1) in normal and malignant human breast tissue. Am J Clin Pathol 118: 451-458, 2002. (Pubitemid 37046344)
50. Brydon L, Roka F, Petit L, Pierre de Coppet, Tissot M, Barrett P, Morgan PJ, Nanoff Ch, Strosberg AD and Jockers R: Dual signaling of human MT1 melatonin receptors via G(i2), G(i3), and G(q/11) proteins. Mol Endocrinol 13: 2025-2038, 1999. (Pubitemid 30637264)
51. Lai L, Yuan L, Cheng Q, Dong Ch, Mao L and Hill SM: Alteration of the MT1 melatonin receptor gene and its expression in primary human breast tumors and breast cancer cell lines. Breast Cancer Res Treat DOI 10.1007/S10549-008-0220- 221, 2008.
52. Houghton AN and Polsky D: Focus on melanoma. Cancer Cell 2(4): 275-278, 2002.
53. Roberts JE, Wiechmann AF and Hu DN: Melatonin receptors in human uveal melanocytes and melanoma cells. J Pineal Res 28: 165-171, 2000.
54. Aust S, Thalhammer T, Humpeler S, Jäger W, Klimpfinger M, Tucek G, Obrist P, Marktl W, Penner E and Ekmekcioglu C: The melatonin receptor subtype MT1 is expressed in human gallbladder epithelia. J Pineal Res 36: 43-48, 2004. (Pubitemid 38130288)
55. Slominski A, Pisarchik A, Zbytek B, Tobin DJ and Kauser S: Functional activity of serotoninergic and melatoninergic systems expressed in the skin. J Cell Physiol 196: 144-153, 2003. (Pubitemid 36676452)
56. Barrett P, Maclean A, Davidson G and Morgan PJ: Regulation of the Mel 1a melatonin receptor mRNA and protein levels in the ovine pars tuberalis: evidence for a cyclic adenosine 3',5' monophosphate independent Mel 1a receptor coupling and an autoregulatory mechanism of expression. Mol Endocrinol 10: 892-902, 1996. (Pubitemid 26234627)
57. Moretti S, Spallanzani A, Chiarugi A, Fabiani M and Pinzi C: Correlation of Ki-67 expression in cutaneous primary melanoma with prognosis in a prospective study: different correlation according to thickness. J Am Acad Dermatol 44:188-192, 2001. (Pubitemid 32172178)